secwatch.observer — SEC 8-K summary
======================================

Issuer:     VERTEX PHARMACEUTICALS INC / MA (VRTX)
CIK:        0000875320
Form:       8-K
Filed at:   2024-06-27T23:59:59+00:00
Accession:  0000875320-24-000178
Event type: other_material
Sentiment:  neutral
Materiality: 0.65
Item codes: 8.01
LLM model:  deepseek-v4-flash:cloud@v2

Vertex expects $4.4B AIPR&D charge and $200M compensation expense from Alpine acquisition in Q2 2024
--------------------------------------------------------------------------------

- Vertex records one-time non-deductible AIPR&D expense of approx. $4.4B in Q2 2024 from Alpine asset acquisition accounting.
- Also expects $200M transaction-related compensation expense for acceleration of unvested Alpine equity awards in Q2 2024.
- Charges will impact GAAP and non-GAAP operating expenses and net income for Q2 and full year 2024, and related guidance.
- Vertex completed Alpine acquisition for $5.0B cash on May 20, 2024; expects to absorb Alpine's non-GAAP R&D/SG&A within existing guidance.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/875320/000087532024000178/0000875320-24-000178-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/875320/000087532024000178/vrtx-20240627.htm
  HTML page:      https://secwatch.observer/filing/0000875320-24-000178

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer